Faropenem PCD Pharma Franchise Company
Cafoli Lifecare offers a Faropenem PCD pharma franchise built on 8 formulations across tablets and dry syrup, all manufactured at WHO-GMP certified facilities. This gives franchise partners a premium oral antibiotic line for physicians and paediatricians.
What is Faropenem?
Faropenem is an orally active beta-lactam antibiotic of the penem class. It inhibits bacterial cell-wall synthesis and shows broad activity against many Gram-positive, Gram-negative and anaerobic organisms, with good stability against many common beta-lactamases. Read its profile on PubChem.
Therapeutic Applications
Faropenem is prescribed for respiratory tract infections, urinary tract infections, skin and soft-tissue infections, ENT infections and gynaecological infections, and is a useful oral step-down option where resistance to standard oral antibiotics is a concern. The dry syrup extends its use to paediatric patients. Prescribers include general physicians, paediatricians, ENT surgeons and gynaecologists.
Why Faropenem is a High-Potential Molecule for Distributors
As one of the few orally available penems, faropenem occupies a niche premium position as a convenient alternative to injectable carbapenems and a step-up when common oral antibiotics fail. Rising antibiotic resistance is steadily increasing its use, and the availability of a paediatric dry syrup broadens the market. That premium, less-crowded positioning gives distributors healthy margins.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- PubChem: Faropenem
- PubMed: Faropenem literature
Our formulations of Faropenem find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: